Amneal Pharmaceuticals
AMRX
161 hedge funds and large institutions have $684M invested in Amneal Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 41 increasing their positions, 46 reducing their positions, and 17 closing their positions.
176% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 17
50% more capital invested
Capital invested by funds: $455M → $684M (+$229M)
21% more funds holding
Funds holding: 133 → 161 (+28)
1.05% more ownership
Funds ownership: 67.39% → 68.44% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less call options, than puts
Call options by funds: $2.4M | Put options by funds: $2.54M
11% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$19.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.2M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$9.61M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$8.96M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$8.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$76.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.76M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$2.52M |
| 4 |
Goldman Sachs
New York
|
-$1.66M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$1.59M |
AMRX Hedge Fund Activity: Q1 2021 in Review
161 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q1 2021, worth a combined $684M — up 50% from $455M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new AMRX positions and 17 closed out — a net gain of 30 holders — while 41 added to existing stakes and 46 trimmed.
The largest buyer was Eversept Partners, adding an estimated $19.8M. The largest seller was Wellington Management Group, cutting an estimated $76.8M.
- 161 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q1 2021, up from 133 in Q4 2020.
- Funds reported $684M of Amneal Pharmaceuticals stock for Q1 2021, up 50% quarter-over-quarter.
- 47 funds opened new Amneal Pharmaceuticals positions in Q1 2021 and 17 closed out, a net change of +30 holders.
- The largest Amneal Pharmaceuticals buyer in Q1 2021 was Eversept Partners, an estimated $19.8M added.
- The largest Amneal Pharmaceuticals seller in Q1 2021 was Wellington Management Group, an estimated $76.8M sold.
Based on aggregated 13F filings for Q1 2021.